Aspira Womens Health Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
AWHL$0.430.0%Stored close · as of Sep 19, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 2. Properties
PROPERTIES
The following chart indicates the facilities that we lease, the location and size of each facility and its designated use. We believe that these facilities are suitable and adequate for our current needs.
| Location | Approximate Square Feet | Primary Functions | Lease Expiration Date |
|---|---|---|---|
| Austin, Texas | 4,218 sq. ft. | Aspira Labs facility, research and development, clinical and regulatory and administrative offices | February 28, 2027 |
| Shelton, Connecticut | 4,614 sq. ft. | Administrative offices | September 30, 2028 |
| Palo Alto, California | 2,714 sq. ft. | Administrative offices | May 31, 2024 |
ITEM 3.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.